Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Agios Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Regeneron Pharmaceuticals Inc. June 12, 202696.0%
-
Prime Medicine Inc. June 5, 202679.5%
-
Denali Therapeutics Inc. June 3, 202673.5%
-
Regeneron Pharmaceuticals Inc. June 14, 202495.1%
-
Prime Medicine Inc. June 14, 202394.3%
-
Denali Therapeutics Inc. June 1, 202383.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 3, 2026 | Denali Therapeutics Inc. | Grant or award | +6,408 | — | — |
| Jan 2, 2026 | Regeneron Pharmaceuticals Inc. | Grant or award | +155 | — | — |
| Jun 3, 2025 | Denali Therapeutics Inc. | Grant or award | +6,037 | — | — |
| Jan 2, 2025 | Regeneron Pharmaceuticals Inc. | Grant or award | +166 | — | — |
| Nov 11, 2024 | Denali Therapeutics Inc. | Option exercise | +47,165 | $18.00 | $848,970 |
| Nov 11, 2024 | Denali Therapeutics Inc. | Open-market sale | −27,129 | $32.09 | $870,570 |
| Nov 11, 2024 | Denali Therapeutics Inc. | Open-market sale | −32,312 | $32.87 | $1,062,095 |
| Jun 13, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +3,388 | — | — |
| May 31, 2024 | Denali Therapeutics Inc. | Grant or award | +5,967 | — | — |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +11,858 | $31.64 | $375,187 |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −11,858 | $33.60 | $398,429 |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +57,471 | $31.64 | $1,818,382 |
| Feb 27, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −57,471 | $34.89 | $2,005,163 |
| Feb 26, 2024 | Agios Pharmaceuticals Inc. | Option exercise | +20,411 | $31.64 | $645,804 |
| Feb 26, 2024 | Agios Pharmaceuticals Inc. | Open-market sale | −20,411 | $33.19 | $677,441 |
Questions about David P. Schenkein
What boards is David P. Schenkein on?
David P. Schenkein sits on the boards of Agios Pharmaceuticals Inc., Denali Therapeutics Inc., Prime Medicine Inc. and Regeneron Pharmaceuticals Inc.
How long has David P. Schenkein served on boards?
Our records show at least 14 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.